LEXIVA Drug Patent Profile
✉ Email this page to a colleague
When do Lexiva patents expire, and when can generic versions of Lexiva launch?
Lexiva is a drug marketed by Viiv Hlthcare and is included in two NDAs.
The generic ingredient in LEXIVA is fosamprenavir calcium. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the fosamprenavir calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lexiva
A generic version of LEXIVA was approved as fosamprenavir calcium by MYLAN on April 15th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LEXIVA?
- What are the global sales for LEXIVA?
- What is Average Wholesale Price for LEXIVA?
Summary for LEXIVA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 55 |
Clinical Trials: | 12 |
Patent Applications: | 427 |
Drug Prices: | Drug price information for LEXIVA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LEXIVA |
What excipients (inactive ingredients) are in LEXIVA? | LEXIVA excipients list |
DailyMed Link: | LEXIVA at DailyMed |
Recent Clinical Trials for LEXIVA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Medical College of Wisconsin | Phase 3 |
ViiV Healthcare | Phase 1 |
GlaxoSmithKline | Phase 1 |
Pharmacology for LEXIVA
Drug Class | Protease Inhibitor |
Mechanism of Action | Cytochrome P450 3A4 Inducers Cytochrome P450 3A4 Inhibitors HIV Protease Inhibitors P-Glycoprotein Inducers |
Paragraph IV (Patent) Challenges for LEXIVA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LEXIVA | Tablets | fosamprenavir calcium | 700 mg | 021548 | 1 | 2012-01-18 |
US Patents and Regulatory Information for LEXIVA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | LEXIVA | fosamprenavir calcium | SUSPENSION;ORAL | 022116-001 | Jun 14, 2007 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Viiv Hlthcare | LEXIVA | fosamprenavir calcium | TABLET;ORAL | 021548-001 | Oct 20, 2003 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LEXIVA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | LEXIVA | fosamprenavir calcium | SUSPENSION;ORAL | 022116-001 | Jun 14, 2007 | ⤷ Sign Up | ⤷ Sign Up |
Viiv Hlthcare | LEXIVA | fosamprenavir calcium | TABLET;ORAL | 021548-001 | Oct 20, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Viiv Hlthcare | LEXIVA | fosamprenavir calcium | TABLET;ORAL | 021548-001 | Oct 20, 2003 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LEXIVA
See the table below for patents covering LEXIVA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Slovenia | 1098898 | ⤷ Sign Up | |
Australia | 5037999 | ⤷ Sign Up | |
Tunisia | SN99145 | CALCIUM (3S) TETRAHYDRO-3-FURANYLE (1S,2R)-3-[[4-AMINOPHENYLE) SULFONYLE] ISOBUTYLE)AMINO]-1-BENZYLE-2-(PHOSPHONOOXY), PROPYLCARBAMATE | ⤷ Sign Up |
Japan | 2009102400 | PRODRUG OF ASPARTYL PROTEASE INHIBITOR | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LEXIVA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0933372 | 324 | Finland | ⤷ Sign Up | |
0933372 | SPC/GB08/018 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712 |
0933372 | 300339 | Netherlands | ⤷ Sign Up | 300339, 20180310, EXPIRES: 20190711 |
0933372 | SPC012/2008 | Ireland | ⤷ Sign Up | SPC012/2008: 20091119, EXPIRES: 20190711 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |